Table 1.
Effects of Different Inhibitors of PGAM1 on Proliferation and Metastasis of Various Cancer
| Involved Organ | PGAM1 Inhibitor | Inhibit Tumor Proliferation | Inhibit Tumor Metastasis | Signal Pathway | References |
|---|---|---|---|---|---|
| Breast cancer | 1) siRNA | / | + | ACTA2 | [23, 28] |
| 2) PGMI-004A | / | — | / | [28] | |
| 3) MJE3 | + | / | / | [21, 22] | |
| 4) Xanthone derivatives | + | / | / | [53] | |
| Glioma | siRNA | + | + | / | [20] |
| HCC | shRNA | + | / | / | [14] |
| Leukemia | PGMI-004A | + | / | / | [28] |
| NSCLC | 1) shRNA | + | / | RTK/PI3K/AKT/mTOR | [15] |
| 2) Compound 9i | + | / | / | [51] | |
| 3) Xanthone derivatives | + | / | / | [53] | |
| 4) EGCG | + | / | / | [52] | |
| 5) PGMI-004A | + | / | / | [28] | |
| 6) HKB99 | + | + | ROS/JNK/c-JUN; ACTA2 | [56] | |
| OSCC | siRNA | / | + | Paxillin/FAK/SRC | [17] |
| PCa | siRNA | + | + | / | [18] |
| PDAC | 1) siRNA | + | + | PI3K/AKT/mTOR | [35] |
| 2) Xanthone derivatives | + | / | / | [53] | |
| 3) KH3 | + | / | / | [55] | |
| UBC | shRNA | + | / | / | [19] |
Notes: “+” means “positive result”, “—” means “negative result”, “/” means “not research”.
Abbreviations: HCC, Hepatocellular carcinoma; NSCLC, Non-small cell lung cancer; OSCC, Oral squamous cell carcinoma; PCa, Prostate cancer; PDAC, Pancreatic ductal adenocarcinoma; UBC, Urothelial bladder cancer.